Stocks
CytomX Therapeutics, Inc.CTMX
NASDAQHealthcareBiotechnology$2.44
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing conditionally activated antibody therapeutics for cancer treatment. Its Probody platform is designed to target tumor-specific conditions, potentially reducing toxicity and improving efficacy. Investors track CTMX for its pipeline progress and partnerships with larger pharmaceutical companies.
52W Range: $2.20-$8.21
Congressional Interest in CytomX Therapeutics, Inc. (CTMX)
No congressional trades have been disclosed for CytomX Therapeutics, Inc. (CTMX) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading CTMX?
No congressional trades found for this stock.